GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Lab] 22th independent test on WXT — 99.2% on a claimed 98.5%, and the trend is the interesting part — 47 comments in the full submission. View in context.
6.3k
c/tirzepatide·submitted 2 years ago by u/laila_wikstrom

[Lab] 22th independent test on WXT — 99.2% on a claimed 98.5%, and the trend is the interesting part

Labbranch of 8 comments

Posting this because the title is the whole finding — 22th independent test on WXT — 99.2% on a claimed 98.5%, and the trend is the interesting part — and a number without its method is a rumour. The numbers the title promised, since a headline without them is worthless: 99.2% and 98.5%. Everything below is context…

Read the full submission and all 47 comments →

This branch

8 comments, started 2 years ago
u/zaid_balogun36 points·2 years ago

the sulphur burps profile is genuinely gentler than people expect coming from sema

replysharereportpermalink
u/hugo_bergstrom25 points·2 years ago

the trials titrated on a calendar, real people titrate on symptoms

replysharereportpermalink
u/kian_ekstrom7 points·2 years ago

the four-week step schedule is the label, not folklore

replysharereportpermalink
u/graph_it_gary20 points·2 years ago·edited

Have you held a step for longer than the four-week minimum at any point?

replysharereportpermalink
u/rania_diallo0 points·2 years ago

Agree. The GIP component is the interesting half and it barely gets discussed outside c/glp1science.

replysharereportpermalink
u/emil_okwuosa1 point·2 years ago

dual agonist, so the GIP arm is doing something the sema threads will not tell you about

replysharereportpermalink
u/alcohol_aversion1 point·2 years ago·edited

2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.

replysharereportpermalink
load more comments (1) →

← back to the whole thread

About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.